Literature DB >> 27543653

Cell cycle arrest caused by MEK/ERK signaling is a mechanism for suppressing growth of antigen-hyperstimulated effector T cells.

Shizuka Ohtsuka1, Shuhei Ogawa1, Ei Wakamatsu1, Ryo Abe2.   

Abstract

Suppression of T-cell growth is an important mechanism for establishment of self-tolerance and prevention of unwanted prolonged immune responses that may cause tissue damage. Although negative selection of potentially self-reactive T cells in the thymus as well as in peripheral tissues has been extensively investigated and well documented, regulatory mechanisms to dampen proliferation of antigen-specific effector T cells in response to antigen stimulation remain largely unknown. Thus, in this work, we focus on the identification of growth suppression mechanisms of antigen-specific effector T cells. In order to address this issue, we investigated the cellular and molecular events in growth suppression of an ovalbumin (OVA)-specific T-cell clone after stimulation with a wide range of OVA-peptide concentrations. We observed that while an optimal dose of peptide leads to cell cycle progression and proliferation, higher doses of peptide reduced cell growth, a phenomenon that was previously termed high-dose suppression. Our analysis of this phenomenon indicated that high-dose suppression is a consequence of cell cycle arrest, but not Fas-Fas ligand-dependent apoptosis or T-cell anergy, and that this growth arrest occurs in S phase, accompanied by reduced expression of CDK2 and cyclin A. Importantly, inhibition of MEK/ERK activation eliminated this growth suppression and cell cycle arrest, while it reduced the proliferative response to optimal antigenic stimulation. These results suggest that cell cycle arrest is the major mechanism regulating antigen-specific effector T-cell expansion, and that the MEK/ERK signaling pathway has both positive and negative effects, depending on the strength of antigenic stimulation. © The Japanese Society for Immunology. 2016. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  T-cell growth suppression; activation-induced cell death; cell cycle arrest; signal transduction

Mesh:

Substances:

Year:  2016        PMID: 27543653      PMCID: PMC5091331          DOI: 10.1093/intimm/dxw037

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  49 in total

1.  Antigen-induced suppression of the proliferative response of T cell clones.

Authors:  G Suzuki; Y Kawase; S Koyasu; I Yahara; Y Kobayashi; R H Schwartz
Journal:  J Immunol       Date:  1988-03-01       Impact factor: 5.422

2.  Sustained activation of the raf-MEK-ERK pathway elicits cytokine unresponsiveness in T cells.

Authors:  D Chen; V Heath; A O'Garra; J Johnston; M McMahon
Journal:  J Immunol       Date:  1999-12-01       Impact factor: 5.422

3.  Clonal deletion as direct consequence of an in vivo T cell response to bacterial superantigen.

Authors:  C Wahl; T Miethke; K Heeg; H Wagner
Journal:  Eur J Immunol       Date:  1993-05       Impact factor: 5.532

4.  Dynamic recruitment of PAK1 to the immunological synapse is mediated by PIX independently of SLP-76 and Vav1.

Authors:  Hyewon Phee; Robert T Abraham; Arthur Weiss
Journal:  Nat Immunol       Date:  2005-05-01       Impact factor: 25.606

5.  The roles of Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice.

Authors:  H K Sytwu; R S Liblau; H O McDevitt
Journal:  Immunity       Date:  1996-07       Impact factor: 31.745

Review 6.  The many roles of FAS receptor signaling in the immune system.

Authors:  Andreas Strasser; Philipp J Jost; Shigekazu Nagata
Journal:  Immunity       Date:  2009-02-20       Impact factor: 31.745

Review 7.  Ras and extracellular signal-regulated kinase signaling in thymocytes and T cells.

Authors:  Robert L Kortum; Alexandre K Rouquette-Jazdanian; Lawrence E Samelson
Journal:  Trends Immunol       Date:  2013-03-15       Impact factor: 16.687

Review 8.  Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation.

Authors:  C J Marshall
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

9.  Parameters controlling the programmed death of mature mouse T lymphocytes in high-dose suppression.

Authors:  J M Critchfield; J C Zúñiga-Pflücker; M J Lenardo
Journal:  Cell Immunol       Date:  1995-01       Impact factor: 4.868

10.  Cell growth cycle block of T cell hybridomas upon activation with antigen.

Authors:  J D Ashwell; R E Cunningham; P D Noguchi; D Hernandez
Journal:  J Exp Med       Date:  1987-01-01       Impact factor: 14.307

View more
  8 in total

1.  BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways.

Authors:  Peng Yue; Taylor Harper; Silvia M Bacot; Monica Chowdhury; Shiowjen Lee; Adovi Akue; Mark A Kukuruga; Tao Wang; Gerald M Feldman
Journal:  Oncoimmunology       Date:  2018-10-29       Impact factor: 8.110

2.  Fibroblast contributes for osteoblastic phenotype in a MAPK-ERK and sonic hedgehog signaling-independent manner.

Authors:  Celio J da Costa Fernandes; Augusto Santana do Nascimento; Rodrigo A da Silva; Willian F Zambuzzi
Journal:  Mol Cell Biochem       Date:  2017-06-03       Impact factor: 3.396

3.  An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes.

Authors:  Abhinav Jaiswal; Akanksha Verma; Ruth Dannenfelser; Marit Melssen; Itay Tirosh; Benjamin Izar; Tae-Gyun Kim; Christopher J Nirschl; K Sanjana P Devi; Walter C Olson; Craig L Slingluff; Victor H Engelhard; Levi Garraway; Aviv Regev; Kira Minkis; Charles H Yoon; Olga Troyanskaya; Olivier Elemento; Mayte Suárez-Fariñas; Niroshana Anandasabapathy
Journal:  Cancer Cell       Date:  2022-05-09       Impact factor: 38.585

4.  Public and private human T-cell clones respond differentially to HCMV antigen when boosted by CD3 copotentiation.

Authors:  Laura R E Becher; Wendy K Nevala; Shari Lee Sutor; Megan Abergel; Michele M Hoffmann; Christopher A Parks; Larry R Pease; Adam G Schrum; Svetomir N Markovic; Diana Gil
Journal:  Blood Adv       Date:  2020-11-10

5.  Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients.

Authors:  Markus Hecht; Friedegund Meier; Lisa Zimmer; Bülent Polat; Carmen Loquai; Carsten Weishaupt; Andrea Forschner; Ralf Gutzmer; Jochen S Utikal; Simone M Goldinger; Michael Geier; Jessica C Hassel; Panagiotis Balermpas; Felix Kiecker; Ricarda Rauschenberg; Ursula Dietrich; Patrick Clemens; Carola Berking; Gerhard Grabenbauer; Dirk Schadendorf; Stephan Grabbe; Gerold Schuler; Rainer Fietkau; Luitpold V Distel; Lucie Heinzerling
Journal:  Br J Cancer       Date:  2018-02-13       Impact factor: 7.640

6.  Salinosporamide A, a Marine-Derived Proteasome Inhibitor, Inhibits T Cell Activation through Regulating Proliferation and the Cell Cycle.

Authors:  Hyun-Su Lee; Gil-Saeng Jeong
Journal:  Molecules       Date:  2020-10-29       Impact factor: 4.411

7.  Cystatin-like protein of sweet orange (CsinCPI-2) modulates pre-osteoblast differentiation via β-Catenin involvement.

Authors:  Willian Fernando Zambuzzi; Gisele Faria; Célio da Costa Fernandes; Victor Manuel Ochoa Rodríguez; Andrea Soares-Costa; Joni Augusto Cirelli; Daniela Morilha Neo Justino; Bárbara Roma
Journal:  J Mater Sci Mater Med       Date:  2021-03-22       Impact factor: 3.896

Review 8.  Targeting ERK-Hippo Interplay in Cancer Therapy.

Authors:  Karel Vališ; Petr Novák
Journal:  Int J Mol Sci       Date:  2020-05-03       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.